Last reviewed · How we verify

Duration of Treatment: 3 months

Organon and Co · Phase 3 active Small molecule

Duration of Treatment: 3 months is a Selective estrogen receptor modulator Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Treatment of endometriosis, Treatment of uterine fibroids.

This drug works by inhibiting the activity of a specific enzyme.

This drug works by inhibiting the activity of a specific enzyme. Used for Treatment of endometriosis, Treatment of uterine fibroids.

At a glance

Generic nameDuration of Treatment: 3 months
SponsorOrganon and Co
Drug classSelective estrogen receptor modulator
TargetEstrogen receptor
ModalitySmall molecule
Therapeutic areaGynecology
PhasePhase 3

Mechanism of action

The drug targets a key enzyme involved in the disease process, thereby reducing the symptoms and slowing disease progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Duration of Treatment: 3 months

What is Duration of Treatment: 3 months?

Duration of Treatment: 3 months is a Selective estrogen receptor modulator drug developed by Organon and Co, indicated for Treatment of endometriosis, Treatment of uterine fibroids.

How does Duration of Treatment: 3 months work?

This drug works by inhibiting the activity of a specific enzyme.

What is Duration of Treatment: 3 months used for?

Duration of Treatment: 3 months is indicated for Treatment of endometriosis, Treatment of uterine fibroids.

Who makes Duration of Treatment: 3 months?

Duration of Treatment: 3 months is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is Duration of Treatment: 3 months in?

Duration of Treatment: 3 months belongs to the Selective estrogen receptor modulator class. See all Selective estrogen receptor modulator drugs at /class/selective-estrogen-receptor-modulator.

What development phase is Duration of Treatment: 3 months in?

Duration of Treatment: 3 months is in Phase 3.

What are the side effects of Duration of Treatment: 3 months?

Common side effects of Duration of Treatment: 3 months include Hot flashes, Vaginal discharge, Headache.

What does Duration of Treatment: 3 months target?

Duration of Treatment: 3 months targets Estrogen receptor and is a Selective estrogen receptor modulator.

Related